Watch-and-wait Approach for Clinical Complete Responders after Neoadjuvant Chemoradiotherapy for Rectal Cancer
CC Law
Hong Kong J Radiol 2017;20:282-90
DOI: 10.12809/hkjr1716915
Neoadjuvant chemoradiotherapy followed by total mesorectal excision is the standard of care for locally advanced rectal cancer. The mean pathological complete response rate following neoadjuvant chemoradiotherapy has been reported to be 12% to 16%. In clinical complete responders after neoadjuvant chemoradiation, a non-operative, watch-and-wait approach is thus proposed to allow for organ preservation. This paper reviews key studies of the watch-and-wait approach following neoadjuvant chemoradiotherapy for rectal cancer to determine its oncological outcomes and safety.
Author's affiliation:
CC Law
Department of Clinical Oncology, Queen Elizabeth Hospital, Jordan, Hong Kong
中文摘要
直腸腺癌新輔助放化療後臨床完全緩解者的觀察等待療法
羅志清
新輔助放化療後全直腸系膜切除是局部晚期直腸腺癌的標準治療。新輔助放化療後的平均病理完全緩解率為12%至16%。於新輔助放化療後有臨床完全緩解的直腸腺癌患者，為保存器官，有建議進行非手術的觀察和等待療法。本文回顧新輔助放化療後觀察和等待療法的重要研究以確定其腫瘤療效和安全性。